Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Valneva
Valneva
Valneva, Pfizer push back timeline for Lyme disease vaccine
Valneva, Pfizer push back timeline for Lyme disease vaccine
BioPharma Dive
Pfizer
Valneva
vaccines
Lyme disease
Flag link:
Major readouts on the horizon for small developers
Major readouts on the horizon for small developers
EP Vantage
Aldeyra Therapeutics
Autolus Therapeutics
Bavarian Nordic
BioXcel Therapeutics
Disc Medicine
Editas Medicine
Immunogen
Lantheus
Mersana Therapeutics
NGM Biopharmaceuticals
Omeros
Roche
Sutro BioPharma
uniQure
Valneva
Viking Therapeutics
Flag link:
Valneva, Pfizer delay end date of Lyme disease vaccine phase 3 trial to 2025
Valneva, Pfizer delay end date of Lyme disease vaccine phase 3 trial to 2025
Seeking Alpha
Pfizer
Valneva
clinical trials
vaccines
Lyme disease
VLA15
Flag link:
FDA accepts Valneva’s chikungunya vaccine BLA for priority review
FDA accepts Valneva’s chikungunya vaccine BLA for priority review
Pharmaceutical Business Review
Valneva
chikungunya virus
vaccine
VLS1553
Flag link:
Pfizer, Valneva remove half of participants from study of Lyme disease shot
Pfizer, Valneva remove half of participants from study of Lyme disease shot
BioPharma Dive
Pfizer
Valneva
clinical trials
vaccines
Lyme disease
VLA15
Flag link:
Weak data as booster for Comirnaty close off opportunity for Valneva's COVID-19 vaccine
Weak data as booster for Comirnaty close off opportunity for Valneva's COVID-19 vaccine
Fierce Biotech
Valneva
Pfizer
BioNTech
vaccines
boosters
COVID-29
Flag link:
Pfizer-Valneva's Lyme vaccine triggers 6-month antibody response, validating phase 3 regimen
Pfizer-Valneva's Lyme vaccine triggers 6-month antibody response, validating phase 3 regimen
Fierce Biotech
Pfizer
Valneva
Lyme disease
vaccines
clinical trials
VLA015
Flag link:
Valneva actively discussing second-generation COVID-19 vaccine with prospective partner
Valneva actively discussing second-generation COVID-19 vaccine with prospective partner
PM Live
Valneva
COVID-19
vaccines
funding
Flag link:
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
BioSpace
Pfizer
Valneva
clinical trials
vaccines
Lyme disease
VLA15
Flag link:
Pfizer Buys Stake in Valneva to Advance Lyme Disease Vaccine
Pfizer Buys Stake in Valneva to Advance Lyme Disease Vaccine
BioSpace
Pfizer
vaccines
Valneva
Lyme disease
Flag link:
Valneva Successfully Completes Lot-to-Lot Consistency Trial for its Single-Shot Chikungunya Vaccine Candidate
Valneva Successfully Completes Lot-to-Lot Consistency Trial for its Single-Shot Chikungunya Vaccine Candidate
BioSpace
Valneva
vaccines
clinical trials
VLA1553
chikungunya virus
Flag link:
Valneva and Pfizer report positive Phase 2 data for Lyme disease vaccine in children
Valneva and Pfizer report positive Phase 2 data for Lyme disease vaccine in children
Biopharma Reporter
Valneva
Pfizer
clinical trials
vaccines
VLA15
Lyme disease
pediatric
Flag link:
Pfizer's $130M Lyme disease vaccine advances to phase 3 after 3rd shot shown to increase antibodies
Pfizer's $130M Lyme disease vaccine advances to phase 3 after 3rd shot shown to increase antibodies
Fierce Biotech
Pfizer
Valneva
vaccines
Lyme disease
clinical trials
VLA15
Flag link:
Small biotech says its Covid-19 vaccine spurs more antibodies than AstraZeneca’s. Will supply deals come now?
Small biotech says its Covid-19 vaccine spurs more antibodies than AstraZeneca’s. Will supply deals come now?
Endpoints
vaccines
COVID-19
AstraZeneca
VLA2001
Valneva
Flag link:
Valneva, hit by COVID contract chaos, sees Lyme disease vaccine drop-off in phase 2, but boosters helping
Valneva, hit by COVID contract chaos, sees Lyme disease vaccine drop-off in phase 2, but boosters helping
Fierce Biotech
Valneva
Pfizer
Lyme disease
clinical trials
vaccines
VLA15
Flag link:
Valneva’s chikungunya vaccine reports positive topline data from Phase 3 trial
Valneva’s chikungunya vaccine reports positive topline data from Phase 3 trial
Biopharma Reporter
Valneva
vaccines
chikungunya virus
clinical trials
Flag link:
Valneva's not too late in COVID-19 as analysts eye $1.1B in 2022 vaccine sales
Valneva's not too late in COVID-19 as analysts eye $1.1B in 2022 vaccine sales
Fierce Pharma
Valneva
COVID-19
vaccines
VLA2001
Flag link:
Valneva joins the phase 3 Covid-19 vaccine club
Valneva joins the phase 3 Covid-19 vaccine club
EP Vantage
Valneva
VLA2001
vaccines
COVID-19
clinical trials
Ocugen
Covaxin
Flag link:
COVID player and Pfizer-partnered Valneva eyes $100M Nasdaq IPO
COVID player and Pfizer-partnered Valneva eyes $100M Nasdaq IPO
Fierce Biotech
Valneva
IPOs
COVID-19
Pfizer
Flag link:
Valneva takes COVID-19 vaccine candidate into Phase 3 trials
Valneva takes COVID-19 vaccine candidate into Phase 3 trials
Biopharma Reporter
Valneva
COVID-19
vaccines
clinical trials
Flag link:
Pages
1
2
next ›
last »